Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Comment by stockbuphoonon Jan 06, 2022 8:39pm
120 Views
Post# 34291360

RE:RE:Ken Galbraith CEO - good luck

RE:RE:Ken Galbraith CEO - good luckOne final thought - in the company press release which refers the business wire article, there is absolutely no mention of his involvement in the debacle at Prometic Life Sciences /  Liminal Biosciences. Very telling!   

aussyspitz wrote:
I saw the news and figured I would warn investors here on this board but you beat me to it. I will echo the same sentiment. Full disclosure I do not hold any ZYME but given Galbreath's history with Prometic/Liminal which I did hold I would absolutely be running to exit my position asap. If your are an existing share holder I would be extremely cautious and if you are thinking about opening a position do your own DD. Prometic/Lmnl went from $3600 to $1 with a large part of that fall under his watch all while receiving a very generous executive compensation/salary.  This is your Viking at Stamford Bridge warning and I will not post on this board again.


<< Previous
Bullboard Posts
Next >>